세포검사로 유두갑상샘암종이 의심되는 갑상샘 결절의 Galectin-3 발현과 BRAF 돌연변이 분석
Galectin-3 Expression and BRAF Mutation in Cases of Cytologically Suspicious Papillary Thyroid Carcinoma
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background : Fine needle aspiration, which is known as the most accurate and cost-effective ethod for diagnosis of thyroid nodule, still may result in indeterminate cases that are pauci-cellular and show minor nuclear atypia, but most cases are associated with suspicion of papillary thyroid carcinoma (PTC). A B-type Raf kinase (BRAF) mutation was found in about half of PTCs and galectin-3 was expressed by malignant tumors, helping us to differentiate malignancies from benign lesions. Methods : Cases studied included histologically 44 confirmed PTC cases and 18 benign cases previously diagnosed as suspicious of PTC using cytologic examination. Cases were analyzed for galectin-3 expression by immunohistochemical staining and BRAF mutation by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) with a new restriction enzyme. Results : All 44 cases of PTC and 8 of 18 benign controls expressed galectin-3. BRAF mutations were found in only 9 of the 44 PTC cases. Assessment of galectin-3 expression demonstrated high sensitivity but low specificity. Evaluation of BRAF mutation revealed high specificity and low sensitivity. Conclusions : This study suggests that the combined application of these two methods for PTC of suspicious cytology is complementary.
Abstract
Background : Fine needle aspiration, which is known as the most accurate and cost-effective ethod for diagnosis of thyroid nodule, still may result in indeterminate cases that are pauci-cellular and show minor nuclear atypia, but most cases are associated with suspicion of papillary thyroid carcinoma (PTC). A B-type Raf kinase (BRAF) mutation was found in about half of PTCs and galectin-3 was expressed by malignant tumors, helping us to differentiate malignancies from benign lesions. Methods : Cases studied included histologically 44 confirmed PTC cases and 18 benign cases previously diagnosed as suspicious of PTC using cytologic examination. Cases were analyzed for galectin-3 expression by immunohistochemical staining and BRAF mutation by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) with a new restriction enzyme. Results : All 44 cases of PTC and 8 of 18 benign controls expressed galectin-3. BRAF mutations were found in only 9 of the 44 PTC cases. Assessment of galectin-3 expression demonstrated high sensitivity but low specificity. Evaluation of BRAF mutation revealed high specificity and low sensitivity. Conclusions : This study suggests that the combined application of these two methods for PTC of suspicious cytology is complementary.
참고문헌 (26)
- Davies L, "Increasing incidence of thyroid cancer in the United States,1973-2002", JAMA, 295, pp.2164~2167 (2006)
- Leenhardt L, "Increased incidence of thyroid carcinoma in France:a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee", Thyroid, 14, pp.1056~1060 (2004)
- Gharib H, "Fine-needle aspiration biopsy of the thyroid:an appraisal", Ann Intern Med, 118, pp.282~289 (1993)
- Rowe LR, "Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules", Cytojournal, 3, pp.10~ (2006)
- Takenaka Y, "Malignant transformation of thyroid follicular cells by galectin-3", Cancer Lett, 195, pp.111~119 (2003)
- Yoshii T, "Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells", Int J Oncol, 18, pp.787~792 (2001)
- Liu YY, "Combined immunostaining with galectin-3,fibronectin-1,CITED-1,Hector Battifora mesothelial-1,cytokeratin-19,peroxisome proliferator-activated receptor-{gamma},and sodium", iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma, 2008, pp.158, 375~384
- Rydlova M, "Potential diagnostic markers in nodular lesions of the thyroid gland:an immunohistochemical study", Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 152, pp.53~59 (2008)
- Semenov Dlu, "Galectin-3 in diagnosis of thyroid cancer", Vopr Onkol, 54, pp.321~323 (2008)
- Nikiforova MN, "Molecular genetics of thyroid cancer:implications for diagnosis,treatment and prognosis", Expert Rev Mol Diagn, 8, pp.83~95 (2008)
- Namba H, "Clinical implication of hot spot BRAF mutation,V599E,in papillary thyroid cancers", J Clin Endocrinol Metab, 88, pp.4393~4397 (2003)
- Adeniran AJ, "Correlation between genetic alterations and microscopic features,clinical manifestations,and prognostic characteristics of thyroid papillary carcinomas", Am J Surg Pathol, 30, pp.216~222 (2006)
- Xing M, "BRAF mutation in papillary thyroid cancer:pathogenic role,molecular bases,and clinical implications", Endocr Rev, 28, pp.742~762 (2007)
- Lee JH, "Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid:a metaanalysis", Cancer, 110, pp.38~46 (2007)
- Liu D, "Suppression of BRAF", MEK, Clin Cancer Res, pp.2007, 13[DOI]
- Lee JH, "BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas", Pathology, 38, pp.201~204 (2006)
- Jo YS, "Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer", J Clin Endocrinol Metab, 91, pp.3667~3670 (2006)
- 김경희, "Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population", Yonsei Medical Journal, 45(5), pp.818~821 (2004), 연세대학교의과대학
- Kim SK, "Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules", Diagn Mol Pathol, 17, pp.118~125 (2008)
- Sapio MR, "Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma", Endocr Relat Cancer, 14, pp.1089~1097 (2007)
- Kelman AS, "Thyroid cytology and the risk of malignancy in thyroid nodules:importance of nuclear atypia in indeterminate specimens", Thyroid, 11, pp.271~277 (2001)
- Oertel YC, "Thyroid cytology and histology", Baillieres Best Pract Res Clin Endocrinol Metab, 14, pp.541~557 (2000)
- Saggiorato E, "Characterization of thyroid‘ follicular neoplasms’in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers:a proposal for clinical application", Endocr Relat Cancer, 12, pp.305~317 (2005)
- Prasad ML, "Galectin-3,fibronectin-1,CITED-1,HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors", Mod Pathol, 18, pp.48~57 (2005)
- Sheu SY, "Diffuse sclerosing variant of papillary thyroid carcinoma:lack of BRAF mutation but occurrence of RET", PTC rearrangements, 2007, pp.20, 779~787
- Santarpia L, "Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma", Hum Pathol, 40, pp.827~833 (2009)